SEC Form 25 filed by Genocea Biosciences Inc.
$GNCA
Biotechnology: Pharmaceutical Preparations
Health Care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________________________________
FORM 25
_______________________________________
NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission File Number 001-36289
_______________________________________
GENOCEA BIOSCIENCES, INC.
THE NASDAQ CAPITAL MARKET
(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
_______________________________________
100 Acorn Park Drive, 5th Floor
Cambridge, MA 02140
(617) 876-8191
(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
Common Stock, par value $0.001 per share
(Description of each class of securities)
_______________________________________
Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
☐ 17 CFR 240.12d2-2(a)(1)
☐ 17 CFR 240.12d2-2(a)(2)
☐ 17 CFR 240.12d2-2(a)(3)
☐ 17 CFR 240.12d2-2(a)(4)
☐ Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.
☒ Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
Pursuant to the requirements of the Securities Exchange Act of 1934, Genocea Biosciences, Inc. certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
| Date: | June 2, 2022 | By: | /s/ Diantha Duvall | |||||||||||
| Name: | Diantha Duvall | |||||||||||||
| Title: | Chief Financial Officer | |||||||||||||